Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA Announces Positive Results from Phase III CLARINET Study of Somatuline Autogel 120mg in Gastrointestinal and Pancreatic Neuroendocrine Tumors


Thursday, 11 Jul 2013 01:00am EDT 

Ipsen SA announced results from the primary endpoint of the CLARINET study, assessing the effect of Somatuline Autogel 120 mg on tumor progression-free survival in patients with GEP-NETs. Treatment with Somatuline Autogel 120mg was found to be statistically significantly superior to placebo in extending time to either disease progression or death. The safety profile observed in the study is consistent with the known safety profile of Somatuline. 

Company Quote

34.1
0.755 +2.26%
11 Jul 2014